Resmed Inc risk profile
26 Normal where most of the sector sits
Measured 1 September 2026 from RMD's filed statements. Recomputed nightly.
26 (Normal), driven by Competitive position at 36, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 29 | Normal | Stable | One-year price volatility — 29.1% |
| Operating pressure | 21 | Normal | Easing | Costs outgrowing revenue — -5.0 percentage points |
| Cash conversion | 22 | Normal | Stable | Cash conversion — 1.25x |
| Leverage and coverage | 5 | Contained | Stable | Current ratio — 3.44x |
| Competitive position | 36 | Normal | Stable | R&D-intensity gap against peers — -7.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.